Asia-Pacific Neuroendocrine Tumors Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2032

Asia-Pacific Neuroendocrine Tumors Market Segmentation, By Classification (Functional Net and Non-Functional Net), Site (Lung, Pancreas, Gastrointestinal Tract (GI), Grade (Grade 1 {Low-Grade Tumor}, Grade 2 {Intermediate-Grade Tumor}, Grade 3 {High-Grade Tumor}), Type (Diagnosis and Treatment), Route of Administration (Oral and Parenteral), Mode of Purchase (Prescription and Over the Counter (OTC)), End User (Hospitals, Specialty Clinics, Radiation Centers, Home Healthcare and Others), Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others) - Industry Trends and Forecast to 2032

Asia-Pacific Neuroendocrine Tumors Market Size

• The Asia-Pacific neuroendocrine tumors market size was valued at USD 601.37 Million in 2024 and is expected to reach USD 1436.61 Million by 2032, at a CAGR of 11.50% during the forecast period
• The market growth is largely fueled by the increasing incidence of neuroendocrine tumors worldwide, rising awareness regarding early diagnosis, and growing demand for effective therapeutic interventions. Advances in imaging technologies, targeted therapies, and minimally invasive surgical procedures are further supporting the expansion of the neuroendocrine tumors market globally
• Furthermore, the rising geriatric population, growing prevalence of associated comorbidities, and improved access to specialized oncology centers are driving the adoption of effective neuroendocrine tumors treatment solutions. These converging factors are accelerating the uptake of surgical, targeted, and systemic therapies, thereby significantly boosting the industry’s growth

Asia-Pacific Neuroendocrine Tumors Market Analysis

• Neuroendocrine Tumors treatment, including surgical resection, peptide receptor radionuclide therapy (PRRT), targeted therapy, and systemic treatments, is increasingly recognized as a critical solution for managing NETs and improving patient outcomes. The rising prevalence of NETs and advancements in diagnostic and therapeutic approaches are driving market expansion globally
• The market growth is primarily fueled by increasing awareness among healthcare providers and patients regarding early detection, advances in minimally invasive surgeries, and improved access to specialized oncology centers. These factors are accelerating the adoption of NETs treatment solutions across regions
• China dominated the neuroendocrine tumors market with the largest revenue share of 28.3% in 2024, driven by its large patient population, advanced healthcare infrastructure, and strong adoption of targeted therapies and specialized treatment options
• India is expected to be the fastest-growing country in the neuroendocrine tumors market with a CAGR of 11.2% during the forecast period, fueled by increasing healthcare awareness, rising disposable incomes, and expanding access to oncology centers
• The Prescription segment captured the largest revenue share of 89.1% in 2024, due to the complexity of NET therapies requiring strict physician oversight. Prescription channels ensure proper dosing, monitoring, and follow-up

Report Scope and Neuroendocrine Tumors Market Segmentation    

Asia-Pacific Neuroendocrine Tumors Market Trends

Emerging Trends in Diagnosis and Targeted Therapies

• A key and accelerating trend in the neuroendocrine tumors (NETs) market is the growing emphasis on precision medicine and targeted therapies. Advances in molecular profiling, genetic testing, and imaging techniques are allowing clinicians to better identify tumor subtypes and tailor treatment plans for individual patients

  • For instance, the use of somatostatin receptor imaging (SRI) combined with PET/CT scans is improving the accuracy of NET detection and staging. Similarly, novel peptide receptor radionuclide therapy (PRRT) agents are enabling more effective treatment with fewer side effects

• Another notable trend is the integration of minimally invasive surgical techniques and interventional radiology procedures, which enhance patient outcomes and reduce recovery times
• Theranostics, which combines therapy and diagnostics, is gaining prominence, allowing simultaneous imaging and treatment of tumors, thereby optimizing treatment efficacy
• There is also a rising adoption of combination therapies, such as targeted therapy with immunotherapy or chemotherapy, to improve patient survival and reduce recurrence rates
• Patient-centric care is becoming more common, with increased focus on quality-of-life assessments, symptom management, and personalized follow-up strategies
• The trend towards earlier diagnosis and targeted interventions is expected to redefine NET management protocols, improve long-term survival, and reduce healthcare costs
• Healthcare providers are increasingly investing in clinical trials and real-world evidence studies to validate the effectiveness of emerging therapies, driving adoption across both developed and emerging markets

Asia-Pacific Neuroendocrine Tumors Market Dynamics

Driver

Rising Prevalence and Awareness of Neuroendocrine tumors

• The increasing incidence of neuroendocrine tumors worldwide is a key growth driver for the market. Improved screening and awareness campaigns are contributing to higher diagnosis rates

  • For instance, a surge in gastroenteropancreatic NET detection in Europe and North America has led to earlier treatment initiation and improved patient outcomes

• Expanding research on NET biomarkers and the development of novel targeted therapies are increasing treatment options and enhancing patient survival
• Healthcare infrastructure improvements, particularly in emerging regions such as Asia-Pacific, are facilitating access to specialized NET treatment centers
• Rising awareness among physicians and patients about advanced imaging techniques and targeted therapies is accelerating adoption
• Supportive care initiatives and patient advocacy programs are further boosting treatment uptake and adherence

Restraint/Challenge

Concerns Regarding High Treatment Costs, Limited Access, and Diagnostic Complexity

• The high cost of neuroendocrine tumor treatments, particularly advanced therapies such as PRRT and biologics, remains a major challenge limiting widespread adoption, especially in low- and middle-income countries

  • For instance, a single PRRT treatment cycle can cost tens of thousands of dollars, posing financial strain even in regions with partial insurance coverage

• Limited access to specialized treatment centers equipped to administer radioligand or targeted therapies further restricts patient reach, especially in rural or underdeveloped healthcare infrastructures
• Delayed or missed diagnoses due to nonspecific symptoms often lead to late-stage detection, reducing therapeutic efficacy and survival rates
• The shortage of trained oncologists and nuclear medicine specialists in several regions adds to treatment delays and impacts the quality of care for patients with NETs
• In addition, stringent regulatory frameworks for radiopharmaceutical development and approval often extend commercialization timelines, hindering the introduction of novel therapies
• High R&D costs, coupled with uncertain reimbursement scenarios for emerging targeted treatments, discourage smaller pharmaceutical players from entering the market
• Furthermore, the emotional and psychological burden on patients, coupled with the complexity of long-term disease management, creates additional challenges in maintaining treatment adherence
• Data fragmentation across healthcare systems limits large-scale epidemiological studies, delaying the development of unified treatment guidelines
• Overcoming these challenges through improved healthcare infrastructure, stronger reimbursement frameworks, and the development of cost-effective diagnostic and treatment alternatives will be crucial for sustained Neuroendocrine Tumors market growth

Asia-Pacific Neuroendocrine Tumors Market Scope

The market is segmented on the basis of classification, site, grade, type, route of administration, mode of purchase, end user, and distribution channel.

• By Classification

On the basis of classification, the Neuroendocrine Tumors market is segmented into Functional NET and Non-Functional NET. The Functional NET segment dominated the market with a 61.4% revenue share in 2024, driven by the high prevalence of hormone-secreting tumors such as insulinomas, gastrinomas, and carcinoid tumors. Functional NETs are often detected earlier due to symptomatic hormone secretion, enabling timely diagnosis and treatment. Adoption of somatostatin analogs, PRRT, and targeted biologics such as everolimus supports segment leadership. Favorable reimbursement policies, rising diagnostic awareness, and improved healthcare access contribute to dominance. Multidisciplinary care and advanced imaging facilities in developed markets like the U.S., Germany, and Japan enhance treatment accuracy. Continuous research in hormonal regulation pathways strengthens patient outcomes. The segment benefits from early-stage detection leading to better prognosis. Functional NET patients often require integrated therapy plans. Hospitals and specialty clinics facilitate advanced treatment adoption. Availability of long-term therapy options ensures consistent revenue growth. Increasing clinical trial activity in hormone-secreting tumors further reinforces leadership. The segment remains the focus of oncology innovation and therapeutic advancements.

The Non-Functional NET segment is projected to witness the fastest CAGR of 9.8% from 2025 to 2032, driven by rising detection of asymptomatic NETs through advanced imaging modalities such as PET-CT and MRI. Molecular profiling and genetic testing improve diagnostic precision, particularly for silent tumors. Adoption of PRRT and radioligand therapies for advanced or metastatic stages fuels growth. Investments in oncology research and increasing awareness among clinicians support rapid expansion. Non-functional tumors, previously underdiagnosed, are increasingly recognized as high-priority treatment targets. Growing patient pools in emerging markets boost segment potential. Improved access to specialized centers enhances uptake. Awareness campaigns and screening programs increase early detection rates. Healthcare infrastructure expansion facilitates delivery of novel therapies. Increased collaborations between hospitals and research centers drive innovation. Government support for oncology research accelerates growth. Market penetration is further strengthened by the rising number of clinical trials. Patient education initiatives on silent NETs contribute to rapid adoption.

• By Site

On the basis of site, the Neuroendocrine Tumors market is segmented into Gastrointestinal Tract (GI) and Pancreas. The Gastrointestinal Tract (GI) segment held the largest revenue share of 48.6% in 2024, driven by high prevalence of small intestine and colorectal NETs. GI NETs benefit from endoscopic diagnostics and advanced imaging techniques for early detection. Favorable reimbursement policies for GI treatments enhance market leadership. Early symptom recognition and multiple therapy options, including somatostatin analogs and targeted biologics, reinforce dominance. Research focus on GI malignancies supports consistent growth. Hospitals and specialty clinics facilitate early intervention. Screening programs and patient awareness campaigns strengthen uptake. Development of advanced biopsy and histopathology techniques improves accuracy. Increasing prevalence of GI malignancies drives treatment demand. Clinical trials targeting digestive system NETs enhance therapeutic innovations. Growth is supported by urban healthcare infrastructure expansion. Adoption of minimally invasive interventions contributes to sustained revenue. The integration of targeted therapies with conventional care ensures effective management.

The Pancreas segment is anticipated to register the fastest CAGR of 10.3% from 2025 to 2032, driven by rising prevalence of pancreatic NETs (pNETs) and strong pipeline development for PRRT and targeted therapies. Molecular imaging and genetic testing enable early detection. Novel drugs such as sunitinib and everolimus improve survival outcomes. Increased government initiatives for rare cancers facilitate clinical trial participation. Precision oncology adoption accelerates diagnosis and treatment planning. Advanced imaging and biomarker screening enhance therapeutic decision-making. Specialized centers for pNET care are expanding. Rising awareness among oncologists and patients supports uptake. Enhanced focus on early intervention drives growth. Outpatient and home-based treatment models encourage adoption. International collaborations in rare cancer research foster innovation. Patient-centric care and monitoring improve compliance. The pipeline of novel therapies ensures sustained market momentum.

• By Grade

On the basis of grade, the Neuroendocrine Tumors market is segmented into Grade 1, Grade 2, and Grade 3. The Grade 2 segment dominated with a 44.8% revenue share in 2024, due to moderate tumor aggressiveness and favorable prognosis. Grade 2 NETs are often detected incidentally or through routine imaging, enabling timely treatment. Availability of targeted biologics, radioligand therapies, and effective patient management enhances segment relevance. Advanced diagnostic tools and biomarkers improve accuracy. Hospitals and specialty centers adopt combination therapy approaches. Clinical guidelines support intermediate-grade NET management. Insurance coverage and reimbursement favor this segment. Multidisciplinary treatment teams improve outcomes. Growing patient population ensures consistent demand. Research in tumor biology supports better therapy options. Awareness campaigns improve early intervention rates. Long-term care programs sustain revenue growth. Improved treatment adherence strengthens market position.

The Grade 3 segment is forecasted to grow at the fastest CAGR of 11.2% from 2025 to 2032, driven by better classification and awareness of aggressive NET variants. Clinical redefinitions separating Grade 3 NETs from NECs have improved diagnostic precision. Immunotherapy and checkpoint inhibitors expand therapeutic options. PRRT adoption in high-grade NETs accelerates treatment access. Oncology research funding fosters novel interventions. Specialized centers and clinical trials support advanced disease management. Advanced imaging and molecular profiling enable precise staging. Physician awareness and training enhance early intervention. Expansion of outpatient care models increases patient access. Emerging markets are adopting improved treatment protocols. Combination therapy strategies improve survival outcomes. Patient-centric treatment approaches enhance adherence. Increased regulatory support for advanced therapies contributes to rapid growth.

• By Type

On the basis of type, the Neuroendocrine Tumors market is segmented into Diagnosis and Treatment. The Treatment segment dominated with a 68.5% revenue share in 2024, driven by high demand for targeted therapies, somatostatin analogs, and PRRT interventions. Expanding healthcare infrastructure supports hospital-based therapy adoption. Improved access to combination therapies strengthens segment leadership. Reimbursement for radioligand therapy ensures widespread use. Long-term disease management programs support sustained revenue. Multidisciplinary oncology teams facilitate personalized treatment. Clinical trial participation expands therapy options. Advanced treatment protocols enhance survival outcomes. Adoption of novel biologics drives patient preference. Growth in emerging markets further strengthens uptake. Government funding for NET therapy supports expansion. Patient-centered care plans enhance adherence. Increasing physician awareness of targeted therapies boosts demand.

The Diagnosis segment is projected to grow at the fastest CAGR of 9.4% from 2025 to 2032, fueled by advancements in molecular imaging, histopathology, and liquid biopsy technologies. AI-based diagnostic systems improve early detection. Expansion of specialized diagnostic labs supports emerging market uptake. Novel biomarker assays enable precise tumor classification. Collaboration between hospitals and diagnostic companies drives innovation. Screening campaigns and patient awareness enhance early detection. Government-funded diagnostic programs encourage testing. Integration of molecular profiling with conventional diagnostics improves outcomes. Access to imaging technologies improves diagnosis in rural areas. Growing prevalence of NETs increases screening demand. Clinician training programs boost adoption. Research in diagnostic innovation supports ongoing market growth. Advanced imaging tools facilitate accurate staging and therapy planning.

• By Route of Administration

On the basis of route of administration, the Neuroendocrine Tumors market is segmented into Parenteral and Oral. The Parenteral segment dominated with a 72.3% revenue share in 2024, as most therapies—including somatostatin analogs and PRRT—require intravenous or subcutaneous delivery. Parenteral administration ensures rapid systemic bioavailability, precise dosing, and consistent therapeutic outcomes. Hospitals and oncology centers continue to adopt parenteral therapy for safe administration. Long-acting injectable formulations support sustained treatment. Clinical trials validate efficacy. Medical supervision ensures patient compliance and minimizes adverse events. Widespread adoption in both palliative and curative care strengthens market dominance. Integration with multidisciplinary care improves outcomes. Adoption in advanced-stage NETs supports revenue. Advanced infusion technologies enhance delivery precision. Government and private hospital support maintains consistent demand. Specialty clinics implement parenteral therapy for complex cases.

The Oral segment is anticipated to register the fastest CAGR of 8.8% from 2025 to 2032, driven by targeted oral therapies such as everolimus and sunitinib. Oral formulations offer patient convenience, long-term maintenance therapy, and reduced hospital dependency. Sustained-release and combination oral drugs enhance adoption. Patient preference for home-based treatment models drives uptake. Clinician awareness and patient education support acceptance. Growth in emerging markets expands access. Telemedicine integration facilitates monitoring and prescription adherence. Reduced logistical burden improves compliance. Increased reimbursement coverage encourages uptake. Outpatient care models support oral therapy adoption. Research in oral formulation optimization strengthens efficacy. Growing patient awareness of alternatives to injections further drives adoption. Advanced oral therapeutics complement parenteral regimens.

• By Mode of Purchase

On the basis of mode of purchase, the Neuroendocrine Tumors market is segmented into Prescription and Over the Counter (OTC). The Prescription segment captured the largest revenue share of 89.1% in 2024, due to the complexity of NET therapies requiring strict physician oversight. Prescription channels ensure proper dosing, monitoring, and follow-up. Hospitals, specialty clinics, and oncology centers support structured treatment pathways. Regulatory requirements and insurance reimbursement favor prescription adoption. Monitoring of therapy outcomes strengthens segment dominance. Multidisciplinary teams optimize adherence. Patient safety considerations maintain high uptake. Access to advanced therapies depends on prescription fulfilment. Clinical guidelines support physician-directed therapy. Hospitals act as central hubs for prescription distribution. Complex biologics require controlled dispensing. Prescription channels enable long-term patient management and compliance.

The Over the Counter (OTC) segment is expected to grow at the fastest CAGR of 7.6% from 2025 to 2032, driven by supportive products including nutritional supplements, symptom relief aids, and wellness formulations. Patient self-care initiatives and quality-of-life considerations boost adoption. Online pharmacies and e-commerce platforms improve accessibility, especially in emerging markets. Retail pharmacy expansion enhances reach. Patient education campaigns encourage use of OTC products alongside NET therapy. Convenience and home delivery support adoption. Awareness of complementary therapies drives uptake. OTC products are increasingly integrated into care pathways. Emerging market penetration strengthens growth. Affordability enhances accessibility. Wellness trends support expansion. Awareness initiatives highlight benefits for supportive care. Collaboration between healthcare providers and retail outlets increases availability.

• By End User

On the basis of end user, the Neuroendocrine Tumors market is segmented into Hospitals and Specialty Clinics. The Hospitals segment dominated with a 54.8% revenue share in 2024, due to their role as central hubs for diagnosis, PRRT administration, and comprehensive NET care. Equipped with PET-CT and MRI imaging, multidisciplinary oncology teams, nuclear medicine facilities, and radiopharmaceutical handling capabilities, hospitals ensure safe, coordinated treatment. Access to advanced diagnostics and radioligand therapies supports dominance. Government and private investments in hospital oncology departments enhance infrastructure. Patient preference for institutional care strengthens market leadership. Hospitals manage complex therapy regimens efficiently. Long-term monitoring ensures optimal outcomes. Integration of diagnostic, treatment, and post-treatment care maintains revenue growth. Availability of clinical trials improves adoption of novel therapies. Patient safety protocols increase reliability. Regulatory compliance supports consistent demand.

The Specialty Clinics segment is projected to grow at the fastest CAGR of 10.9% from 2025 to 2032, driven by expansion of oncology-focused clinics offering patient-centered NET care. Personalized and less crowded environments improve patient experience. Shorter waiting times and tailored therapy plans enhance adoption. Precision medicine and targeted therapy availability fuel demand. Outpatient care models allow continuous monitoring without hospital admission. Collaboration with research organizations promotes advanced therapy access. Awareness campaigns and patient education increase uptake. Integration with local healthcare infrastructure expands reach. Specialty clinics facilitate early diagnosis and intervention. Personalized care strengthens treatment adherence. Flexible scheduling supports patient convenience. Emerging markets benefit from specialized clinic expansion. Growth in outpatient oncology services drives revenue.

• By Distribution Channel

On the basis of distribution channel, the Neuroendocrine Tumors market is segmented into Hospital Pharmacies and Online Pharmacies. The Hospital Pharmacies segment held the largest share of 47.7% in 2024, as hospitals remain the primary channel for high-cost and regulated NET medications. Specialized storage, trained pharmacists, and bulk procurement programs ensure safe, accurate, and efficient drug distribution. Government collaborations and tender-based supply chains enhance reliability. Hospital pharmacies support both inpatient and outpatient care. Centralized distribution ensures compliance with clinical protocols. Continuous access to life-saving therapies maintains revenue. Integration with hospital oncology departments strengthens control over drug usage. Patient monitoring and follow-up improve treatment adherence. Availability of high-demand medications supports leadership. Partnerships with pharmaceutical manufacturers ensure supply continuity. Cost-effective procurement and government contracts enhance operational efficiency. Clinical safety measures reinforce adoption.

The Online Pharmacies segment is projected to grow at the fastest CAGR of 11.4% from 2025 to 2032, fueled by digital healthcare adoption, telemedicine integration, and patient preference for convenience. Online platforms offer doorstep delivery, easy prescription uploads, and automated refills. Collaboration with hospitals and insurance providers enhances trust. Remote access reduces travel burdens for long-term NET therapy patients. Emerging markets benefit from improved access. Competitive pricing and discrete packaging support adoption. Expanded product availability, including supportive care items, drives revenue. Patient education and awareness campaigns encourage utilization. Integration with e-health platforms strengthens monitoring. Data security measures improve patient confidence. Home delivery and subscription services increase convenience. Online pharmacies provide timely access to rare and high-cost therapies. Continuous technological advancements support rapid segment growth.

Asia-Pacific Neuroendocrine Tumors Market Regional Analysis

• The Asia-Pacific neuroendocrine tumors market is poised to grow at the fastest CAGR during the forecast period of 2025 to 2032
• Driven by increasing healthcare awareness, rising disposable incomes, and expanding access to specialized oncology centers in countries such as China and India. The region’s growing focus on early diagnosis and adoption of targeted therapies is further propelling market growth
• Increasing investments in healthcare infrastructure, government initiatives to improve cancer care, and the expansion of private hospitals and specialty clinics are supporting greater patient access to advanced NET treatments

China Neuroendocrine Tumors Market Insight

The China neuroendocrine tumors market accounted for the largest market revenue share of 28.3% in 2024, driven by its large patient population, advanced healthcare infrastructure, and strong adoption of targeted therapies and specialized treatment options. Rapid urbanization, growing healthcare awareness, and government initiatives supporting oncology care further boost market expansion. Advanced hospitals and specialized NET treatment centers facilitate early diagnosis and intervention. Availability of radioligand therapy, peptide receptor therapies, and somatostatin analogs contribute to widespread adoption. Increasing investment in healthcare technology and digital health platforms enhances patient management and access. Rising public awareness, screening programs, and oncology research support market leadership. Collaborations between domestic manufacturers and international pharma companies expand treatment availability. Urban centers with well-equipped oncology facilities strengthen clinical outcomes. Expanding healthcare insurance coverage promotes patient access to costly therapies. Government funding for rare cancer research and the growing clinical trial ecosystem enhance innovation. China’s position as a leader in advanced oncology treatment ensures sustained market dominance in the APAC region.

India Neuroendocrine Tumors Market Insight

The India Neuroendocrine Tumors market is expected to register the fastest growth CAGR of 11.2% in APAC, driven by rising awareness of NETs, growing middle-class population, and enhanced accessibility to oncology centers across urban and semi-urban regions. Increasing adoption of targeted therapies, somatostatin analogs, and PRRT interventions is supporting market expansion. Government health programs, insurance coverage improvements, and public-private partnerships are facilitating patient access to advanced treatments. In addition, growing diagnostic capabilities through molecular imaging and PET-CT availability are improving early detection rates. Rising patient education and awareness campaigns are contributing to higher treatment uptake. Expansion of specialized NET clinics and telemedicine services enhances accessibility in remote regions. Increased investments in training oncology specialists further strengthen market growth. Rising prevalence of gastrointestinal and pancreatic NETs is driving demand for effective therapies.

Asia-Pacific Neuroendocrine Tumors Market Share

The Neuroendocrine Tumors industry is primarily led by well-established companies, including:

• Novartis AG (Switzerland)
• Takeda Pharmaceutical Company Limited (Japan)
• Sun Pharmaceutical Industries Ltd. (India)
• Cipla Ltd. (India)
• Biocon Ltd. (India)
• Shanghai Fosun Pharmaceutical Group Co., Ltd. (China)
• Dr. Reddy’s Laboratories Ltd. (India)

Latest Developments in Asia-Pacific Neuroendocrine Tumors Market

• In March 2024, Orano Med and RadioMedix received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for AlphaMedix (²¹²Pb-DOTAMTATE), a targeted alpha therapy developed for the treatment of inoperable or metastatic, progressive somatostatin receptor-expressing gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This milestone recognition underscores the therapy’s potential to offer improved outcomes for patients with advanced NETs through its precise and potent alpha-emitting radiotherapeutic approach
• In September 2024, Sanofi entered into an exclusive global licensing agreement with RadioMedix, Inc. and Orano Med to co-develop and commercialize AlphaMedix. The collaboration strengthens Sanofi’s oncology pipeline and aims to accelerate global access to this first-in-class alpha-emitter radioligand therapy for NETs, highlighting the growing industry focus on radiopharmaceutical innovations
• In March 2025, the U.S. FDA approved Cabozantinib (CABOMETYX) for the treatment of previously treated advanced neuroendocrine tumors. The approval, supported by research from Dana-Farber Cancer Institute, marked a major advancement in targeted therapy for NETs, offering a novel mechanism that simultaneously inhibits multiple tyrosine kinases involved in tumor growth and angiogenesis
• In November 2024, a comprehensive market and clinical analysis by DelveInsight revealed a strong global trend toward the adoption of radioligand therapies in NET treatment. The report emphasized the shift from traditional beta-emitters (such as Lutetium-177) toward newer, more precise alpha-emitter therapies (such as Lead-212 and Actinium-225). This evolution reflects growing confidence among oncologists and investors in the efficacy and safety of alpha-based radiotherapies for improving progression-free survival in NET patient

SKU-61525